BSE:541096

Stock Analysis Report

Executive Summary

Bharat Parenterals Limited manufactures and sells pharmaceutical formulations in India and internationally.

Snowflake

Fundamentals

Flawless balance sheet with outstanding track record.

Share Price & News

How has Bharat Parenterals's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-2.8%

541096

3.0%

IN Pharmaceuticals

3.1%

IN Market


1 Year Return

-3.3%

541096

-18.9%

IN Pharmaceuticals

3.7%

IN Market

Return vs Industry: 541096 exceeded the Indian Pharmaceuticals industry which returned -18.9% over the past year.

Return vs Market: 541096 underperformed the Indian Market which returned 3.7% over the past year.


Shareholder returns

541096IndustryMarket
7 Day-2.8%3.0%3.1%
30 Day-6.9%-4.2%5.7%
90 Day-4.0%-2.5%1.4%
1 Year-3.3%-3.3%-18.2%-18.9%5.9%3.7%
3 Yearn/a-26.1%-27.6%22.3%16.0%
5 Yearn/a-11.7%-14.3%42.5%28.9%

Price Volatility Vs. Market

How volatile is Bharat Parenterals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Bharat Parenterals undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Undervalued: 541096 (₹175) is trading below our estimate of fair value (₹2617.45)

Significantly Undervalued: 541096 is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: 541096 is good value based on its PE Ratio (4.7x) compared to the Pharmaceuticals industry average (15.8x).

PE vs Market: 541096 is good value based on its PE Ratio (4.7x) compared to the Indian market (13.2x).


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate 541096's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 541096 is good value based on its PB Ratio (1.1x) compared to the IN Pharmaceuticals industry average (1.5x).


Next Steps

Future Growth

How is Bharat Parenterals forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

0.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 541096's forecast earnings growth (0.2% per year) is below the savings rate (7.6%).

Earnings vs Market: 541096's earnings (0.2% per year) are forecast to grow slower than the Indian market (18.2% per year).

High Growth Earnings: 541096's earnings are forecast to grow, but not significantly.

Revenue vs Market: Insufficient data to determine if 541096's revenue is forecast to grow faster than the Indian market.

High Growth Revenue: Insufficient data to determine if 541096's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

High Future ROE: Insufficient data to determine if 541096's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Bharat Parenterals performed over the past 5 years?

23.0%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: 541096's earnings have grown significantly by 23% per year over the past 5 years.

Accelerating Growth: 541096's earnings growth over the past year (133.1%) exceeds its 5-year average (23% per year).

Earnings vs Industry: 541096 earnings growth over the past year (133.1%) exceeded the Pharmaceuticals industry 14.4%.


Return on Equity

High ROE: 541096's Return on Equity (22.6%) is considered high.


Return on Assets

ROA vs Industry: 541096 has a higher Return on Assets than the Pharmaceuticals industry average last year.


Return on Capital Employed

ROCE Improving: 541096 has significantly improved its Return on Capital Employed over the past 3 years.


Next Steps

Financial Health

How is Bharat Parenterals's financial position?


Financial Position Analysis

Short Term Liabilities: 541096's short term assets (₹1.2B) exceeds its short term liabilities (₹605.1M)

Long Term Liabilities: 541096's short term assets (1.2B) exceeds its long term liabilities (44.2M)


Debt to Equity History and Analysis

Debt Level: 541096's debt to equity ratio (5.1%) is considered satisfactory

Reducing Debt: 541096's debt to equity ratio has reduced from 49.3% to 5.1% over the past 5 years.

Debt Coverage: 541096's debt is well covered by operating cash flow (422.5%).

Interest Coverage: 541096's interest payments on its debt are well covered by EBIT (519.9x coverage).


Balance Sheet

Inventory Level: 541096 has a high level of physical assets or inventory.

Debt Coverage by Assets: 541096's debt is covered by short term assets (assets are 24.402670x debt).


Next Steps

Dividend

What is Bharat Parenterals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%0.6%markettop25%2.5%industryaverage0.9%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate 541096's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 541096's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if 541096's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 541096's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 541096's dividend in 3 years as they are not forecast to pay a notable one for the Indian market.


Next Steps

Management

What is the CEO of Bharat Parenterals's salary, the management and board of directors tenure and is there insider trading?

₹14m

CEO Compensation


CEO

Bharat Desai (56yo)

0yrs

Tenure

₹13,800,000

Compensation

Mr. Bharat R. Desai serves as Chairman and Managing Director of Bharat Parenterals Limited. 


CEO Compensation Analysis

Compensation vs. Market: Insufficient data to establish whether Bharat's total compensation is reasonable compared to companies of similar size in the Indian market.

Compensation vs Earnings: Bharat's compensation has increased by more than 20% in the past year.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Bharat Desai (56yo)

    Chairman & MD

    • Tenure: 0yrs
    • Compensation: ₹13.80m
  • Hemang Shah (51yo)

    Executive Director

    • Tenure: 9.3yrs
    • Compensation: ₹1.97m
  • Monica Ahir

    Company Secretary & Compliance Officer

    • Tenure: 0yrs
  • Jignesh Shah

    Chief Financial Officer

    • Tenure: 1.2yrs

Board Members

  • Bharat Desai (56yo)

    Chairman & MD

    • Tenure: 0yrs
    • Compensation: ₹13.80m
  • Hemang Shah (51yo)

    Executive Director

    • Tenure: 9.3yrs
    • Compensation: ₹1.97m
  • Shaileshkumar Gabhawala

    Independent Director

    • Tenure: 0yrs
    • Compensation: ₹15.00k
  • Zankhana Sheth

    Independent Director

    • Tenure: 1.2yrs
    • Compensation: ₹15.00k

Company Information

Bharat Parenterals Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Bharat Parenterals Limited
  • Ticker: 541096
  • Exchange: BSE
  • Founded: 1992
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: ₹1.003b
  • Shares outstanding: 5.73m
  • Website: https://bplindia.in

Location

  • Bharat Parenterals Limited
  • Shree Avenue
  • 1st Floor
  • Vadodara
  • Gujarat
  • 390022
  • India

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
541096BSE (Mumbai Stock Exchange)YesEquity SharesININRMar 2018

Biography

Bharat Parenterals Limited manufactures and sells pharmaceutical formulations in India and internationally. It offers products in the areas of anti retroviral, cephalosporins antibiotics, antiprotozoal/ant ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/18 12:52
End of Day Share Price2019/10/17 00:00
Earnings2019/03/31
Annual Earnings2019/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.